Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

NCT00330759 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1779

Enrollment

INDUSTRY

Sponsor class

Conditions

Bone Metastases

Interventions

BIOLOGICAL: Denosumab
DRUG: Zoledronic Acid

Sponsor

Amgen